Blinklab Limited (ASX:BB1)

Mr Brian Leedman is an experienced biotechnology entrepreneur with over 15 years’ experience in the biotechnology industry. Mr Leedman is the founder of ResApp Health Limited where Mr Leedman served as the executive director of corporate affairs. ResApp Health Limited was acquired by Pfizer (Aust) in 2022. Mr Leedman is an experienced public company director having formerly been the chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and was a director of Alcidion Corporation Limited, Oncosil Medical Limited and Respiri Limited.

Dr Uvarov has significant experience in the healthcare industry with a particular focus on neuroscience. Dr Uvarov has started his career in biotechnology investments as equities analyst with Citigroup. He is a co-founding director of several publicly listed companies in Australia including clinical stage companies such as Dimerix (ASX:DXB), Actinogen Medical (ASX:ACW) and Neuroscientific Biopharmaceuticals (ASX:NSB). He was previously on the board of Imugene (ASX:IMU), a late-stage clinical oncology company.

Ms Jane Morgan is a founder and director of JMM, a boutique investor relations and media communications consultancy group, that for over 16 years, has been providing strategic investor and media relations services to ASX listed companies, across a diverse range of industries including mining and resources, food and beverage, technology, SaaS, fintech, biotech and consumer goods.

Dr Richard Hopkins is an experienced bio-pharmaceutical executive with over 20 years in corporate leadership roles with public biotechnology companies. Dr Hopkins recently served as the managing director for Zelira Therapeutics (ASX: ZLD), a leading global company focused on clinical validation of medical cannabis. Prior to this, Dr Hopkins served as chief executive officer at PharmAust (ASX: PAA) where he oversaw clinical development of a novel cancer therapy for dogs and humans. He was also co-founder and managing director at Phylogica (ASX: PYC), where, in addition to the chief executive officer role, he served in a variate of positions, including chief scientific officer and chief operating officer.